SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 8, 2021
CELLECTAR BIOSCIENCES, INC.
(Exact name of registrant as specified in its charter)
|(State or other jurisdiction|
100 Campus Drive, Florham Park, New Jersey 07932
(Address of principal executive offices, and zip code)
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|¨||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|¨||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol(s)||Name of each exchange on which|
|Common stock, par value $0.00001||CLRB||NASDAQ Capital Market|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
|ITEM 7.01||REGULATION FD DISCLOSURE|
On December 8, 2021, Cellectar Biosciences, Inc. (the “Company”) issued a press announcing its poster presentation at the 63rd American Society for Hematology Annual Meeting and Exposition (the “ASH Meeting”). A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.
On December 13, 2021, the Company issued a press release announcing that the Company has presented data from its ongoing Phase 2 CLOVER-1 Study of Iopofosine I-131 at the ASH Meeting. A copy of the press release is furnished as Exhibit 99.2 and is incorporated by reference herein.
The information in this Item 7.01 and Exhibits 99.1 and 99.2 is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, and shall not be incorporated by reference into any Company filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
|ITEM 9.01||FINANCIAL STATEMENTS AND EXHIBITS|
|99.1||Press release dated December 8, 2021, titled “Cellectar Biosciences Announces Poster Presentation at the 63rd American Society for Hematology Annual Meeting and Exposition”|
|99.2||Press release dated December 13, 2021, titled “Cellectar Presented Data from its Ongoing Phase 2 CLOVER-1 Study of Iopofosine I-131 at the 63rd ASH Annual Meeting and Exposition”|
|104||Cover Page Interactive Data File (embedded within the Inline XBRL Document)|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Dated: December 14, 2021||CELLECTAR BIOSCIENCES, INC.|
|By:||/s/ Dov Elefant|
|Title:||Chief Financial Officer|